PUT/ROCHE GS/200/0.1/21.06.24 Stock

Warrant

DE000GZ36KA2

Market Closed - BOERSE MUENCHEN 14:25:20 2024-06-20 EDT
0.002 EUR -50.00% Intraday chart for PUT/ROCHE GS/200/0.1/21.06.24
Current month-77.78%
1 month-88.89%
Date Price Change
24-06-20 0.002 -50.00%
24-06-19 0.004 -33.33%
24-06-18 0.006 -25.00%
24-06-17 0.008 +14.29%
24-06-14 0.007 0.00%

Real-time BOERSE MUENCHEN

Last update June 20, 2024 at 02:25 pm

More quotes

Static data

Product typeWarrants
Buy / SellPUT
Underlying ROCHE HOLDING AG
Issuer Goldman Sachs
WKN GZ36KA
ISINDE000GZ36KA2
Date issued 2022-11-11
Strike 200 CHF
Maturity Today (1 Days)
Parity 10 : 1
Emission price 0.39
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.584
Lowest since issue 0.001
Delta0x
Omega 0.000000
Premium0x
Gearing173.38x
Moneyness 0.8000
Difference Strike -50 CHF
Difference Strike %-25.00%
Spread 0.298
Spread %99.33%
Intrinsic value 0.000000
Present value 0.1520

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
250 CHF
Average target price
278.1 CHF
Spread / Average Target
+11.22%
Consensus